Author: admin

What was the design of the ReNeu trial examining mirdametinib in NF1-PN?

The multicenter, single-arm ReNeu study enrolled patients at least 2 years of age with symptomatic, inoperable NF1-associated PN causing significant morbidity; of the 114 patients enrolled, 56 were children ranging from 2 years of age to 17 years of age, and 58 were adults who were 18 years of age or older.^1,3

For the treatment phase, patients were administered mirdametinib as a capsule or dispersible tablet at a twice-daily dose of 2 mg/m² as part of a 3-weeks-on/1-week-off schedule. Treatment continued until progressive disease or intolerable toxicity.³

After the treatment phase, patients entered a 30-day safety follow-up period, and they were assessed for eligibility for optional LTFU.¹ Specifically, 84% of adults (n = 26/31) and 86% of children (n = 32/37) elected to continue mirdametinib in the LTFU period. This was followed by another 30-day safety follow-up period.

Key trial end points comprised BICR-assessed confirmed ORR, which was defined as the percentage of patients who experienced a reduction in target PN volume of at least 20% by MRI on consecutive scans at any time before data cutoff; change in target PN volume from baseline; DOR; and safety and tolerability.

In the adult population, the median age was 34 years (range, 18-69), 64% were female, the median volume of target PN was 196 mL (range, 1-3457), and 53% had target PN progressing at the time of trial entry. The most common location of target PN was head and neck (48%), followed by lower/upper extremities (29%), paraspinal (9%), torso (9%), and other (5%). The most common type of PN-related morbidity was pain (90%), followed by disfigurement or major deformity (52%), motor dysfunction or weakness (40%), other (17%), or airway dysfunction (5%).

In the pediatric population, the median age was 10 years (range, 2-17), 54% were female, the median volume of target PN was 99 mL (range, 5-3630), and 62% of patients had target PN progressing at the time of entering the trial. Again, the most common location of target PN was head and neck (50%), followed by lower/upper extremities (14%), torso (14%), other (14%), and paraspinal (7%). The most common type of PN-related morbidity in this population was again pain (70%), followed by disfigurement or major deformity (50%), motor dysfunction or weakness (27%), other (21%), and airway dysfunction (12%).

What was learned about the long-term safety profile of mirdametinib in NF1-associated PN?

No new drug-related safety signals emerged with LTFU.

In the adult population, any-grade treatment-related adverse effects (TRAEs) occurred in 98% of patients, 17% of which were grade 3 or higher. The most common TRAEs experienced by at least 20% of patients included dermatitis acneiform (any grade, 78%; grade ≥3, 9%), diarrhea (48%; 0%), and nausea (36%; 0%). Serious TRAEs were experienced by 2% of patients. Additionally, TRAEs led to dose reductions, interruptions, or discontinuations for 17%, 9%, and 22% of patients, respectively.

In the pediatric population, any-grade TRAEs occurred in 95% of patients; 25% of cases were grade 3 or higher in severity. The most common TRAEs in this population were, again, dermatitis acneiform (any grade, 43%; grade ≥3, 2%), diarrhea (38%; 2%), and nausea (21%; 0%). TRAEs led to dose reductions, interruptions, or discontinuations for 14%, 14%, and 9% of patients, respectively.

“No additional serious TRAEs [and] no additional dose interruptions [were observed]; [there was] 1 additional dose reduction and 1 additional discontinuation due to TRAEs compared to the prior data cutoff,” Hirbe noted in the presentation.

What prior data have been reported from ReNeu?

Previous data showed that in adult patients (n = 58), the confirmed ORR was 41% (95% CI, 29%-55%) with 88% of patients experiencing a DOR of at least 12 months and 50% experiencing a DOR of at least 24 months.³ In pediatric patients, the confirmed ORR with mirdametinib was 52% (95% CI, 38%-65%), with 90% and 48% of patients experiencing a DOR lasting for at least 12 or 24 months, respectively. Early, sustained, and clinically meaningful improvements in pain and health-related quality of life (QOL) were also reported.⁴

The prior data supported the February 2025 FDA approval of mirdametinib for adult and pediatric patients aged 2 years and older with NF1 who have symptomatic PN not amenable to complete resection.⁵ At the time of the decision, Christopher L. Moertel, MD, told OncLive in an exclusive interview:^6,7 “The approval of mirdametinib is significant because this a highly selective MEK inhibitor that will provide benefit to both adults and children with neurofibromatosis type 1 who have plexiform neurofibromas that are not amenable to surgery and are causing significant QOL or pain issues.”

Moertel serves as a pediatric neuro-oncologist and professor at the University of Minnesota School of Medicine in Minneapolis, where he directs the Pediatric Neuro-Oncology Fellowship Program and co-leads the Pediatric Neuro-Oncology and Neurofibromatosis Programs. Listen to the interview via OncLive On Air.⁸

Moreover, in July 2025, the European Commission granted conditional marketing authorization for mirdametinib (Ezmekly) for the same indication based on ReNeu data.⁹ In another exclusive interview with OncLive,¹⁰Ignacio Blanco, MD, PhD, director of the Catalan Reference Center for Neurofibromatosis in Barcelona, Spain, discussed the significance of this decision: “For Europeans, this is a great achievement because…we had no treatment for adult patients with NF1‑associated PNs. In the context of NF1, there are a lot of adult patients with symptomatic PNs where [there was] no possibility to offer anything.” Listen to the full OncLive On Air podcast episode.¹¹

References

1. Hirbe AC, Moertel CL, Shuhaiber HH, et al. Update from the long-term follow-up (LTFU) phase of ReNeu: A pivotal phase 2b trial of mirdametinib in adults and children with neurofibromatosis type 1 (NF1)-associated symptomatic plexiform neurofibroma (PN). Presented at: 2025 SNO Annual Meeting; November 19-23, 2025; Honolulu, Hawaii. Abstract CTNI-06.
2. Hirbe AC. Dr Hirbe on long-term efficacy and safety outcomes with mirdametinib in symptomatic NF1-PN. OncLive.com. November 22, 2025. Accessed November 22, 2025. https://www.onclive.com/view/dr-hirbe-on-long-term-efficacy-and-safety-outcomes-with-mirdametinib-in-symptomatic-nf1-pn
3. Gomekli. Prescribing information; SpringWorks Therapeutics; 2025. https://springworkstx.com/wp-content/uploads/2025/02/GOMEKLI-USPI-Final-Feb-11-2025_.pdf
4. Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: a pivotal phase 2b trial of mirdametinib in adults and children with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN). J Clin Oncol. 2024;42(suppl 16):3016. doi:10.1200/JCO.2024.42.16_suppl.3016
5. FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection. FDA. Feburary 11, 2025. Accessed November 22, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic
6. Moertel CL. Dr Moertel on the FDA approval of mirdametinib for NF1-associated plexiform neurofibromas. OncLive.com. February 11, 2025. Accessed November 22, 2025. https://www.onclive.com/view/dr-moertel-on-the-fda-approval-of-mirdametinib-for-nf1-associated-plexiform-neurofibromas
7. DiEugenio J. Mirdametinib provides long-awaited treatment option in NF1-associated PN: Q&A with Christopher L. Moertel, MD. OncLive.com. February 18, 2025. Accessed November 22, 2025. https://www.onclive.com/view/mirdametinib-provides-long-awaited-treatment-option-in-nf1-associated-pn
8. Moertel CL. FDA Approval Insights: Mirdametinib for NF1-associated plexiform neurofibromas: with Christopher L. Moertel, MD. OncLive.com. February 20, 2025. Accessed November 22, 2025. https://www.onclive.com/view/da-approval-insights-mirdametinib-for-nf1-associated-plexiform-neurofibromas-with-christopher-l-moertel-md
9. The European Commission has granted conditional approval of Ezmekly (mirdametinib) for the treatment of adult and pediatric patients with neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PN). News release. SpringWorks Therapeutics. July 18, 2025. Accessed November 22, 2025. https://springworkstx.gcs-web.com/news-releases/news-release-details/european-commission-grants-conditional-approval-ezmeklyr
10. Blanco I. Dr Blanco on the conditional EU approval of mirdametinib for NF1-associated PNs. OncLive.com. July 31, 2025. Accessed November 22, 2025. https://www.onclive.com/view/dr-blanco-on-the-conditional-eu-approval-of-mirdametinib-for-nf1-associated-pns
11. Blanco I. The European approval of mirdametinib expands the treatment paradigm for NF1-associated plexiform neurofibromas: with Ignacio Blanco, MD, PhD. OncLive.com. August 7, 2025. Accessed November 22, 2025. https://www.onclive.com/view/the-european-approval-of-mirdametinib-expands-the-treatment-paradigm-for-nf1-associated-plexiform-neurofibromas-with-ignacio-blanco-md-phd

• Earlier this month, JFrog unveiled new AI governance capabilities at swampUP Europe, introducing Shadow AI Detection to its Software Supply Chain Platform to help enterprises monitor and control the use of AI models and APIs.

• This development specifically addresses mounting organizational concerns about unapproved AI adoption by automatically discovering and cataloging both internal and third-party AI assets for improved oversight and compliance.

• We’ll explore how JFrog’s Shadow AI Detection addresses regulatory requirements and its potential impact on the company’s investment outlook.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Investors in JFrog need to believe in the company’s ability to lead software supply chain security and governance, particularly as AI adoption and regulatory scrutiny accelerate. The introduction of Shadow AI Detection addresses a key short-term catalyst, customer security and compliance needs, but does not immediately resolve the risk of elongated enterprise sales cycles and cloud migration challenges, which could still impact near-term revenue and margin expectations.

JFrog’s earlier rollout of an enhanced AI Catalog is especially relevant, as both announcements strengthen the company’s value proposition in secure, centralized AI model management for enterprises. This suite of recent product updates plays directly into rising regulatory and security demands, reinforcing JFrog’s positioning as a trusted provider of unified DevSecOps solutions supporting multi-cloud and hybrid environments.

However, against these growth opportunities, investors should be aware that if large enterprise deals are lost or delayed, resulting earnings volatility could …

Read the full narrative on JFrog (it’s free!)

JFrog’s narrative projects $736.3 million revenue and $96.4 million earnings by 2028. This requires 15.8% yearly revenue growth and a $182.7 million increase in earnings from -$86.3 million.

Uncover how JFrog’s forecasts yield a $56.44 fair value, a 5% downside to its current price.

Five Simply Wall St Community fair value estimates for JFrog span a wide range from US$37.57 to US$141.21 per share. While opinions differ, keep in mind that rising demand for secure software supply chains is a central theme shaping the company’s outlook.

Explore 5 other fair value estimates on JFrog – why the stock might be worth over 2x more than the current price!

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

• A great starting point for your JFrog research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

• Our free JFrog research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate JFrog’s overall financial health at a glance.

Our daily scans reveal stocks with breakout potential. Don’t miss this chance:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include FROG.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com